Market Research Logo

Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015

Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015’, provides an overview of the Bipolar Disorder (Manic Depression)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Bipolar Disorder (Manic Depression) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Bipolar Disorder (Manic Depression) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Bipolar Disorder (Manic Depression) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Bipolar Disorder (Manic Depression)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Bipolar Disorder (Manic Depression) Overview
Therapeutics Development
Pipeline Products for Bipolar Disorder (Manic Depression) - Overview
Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis
Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies
Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes
Bipolar Disorder (Manic Depression) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bipolar Disorder (Manic Depression) - Products under Development by Companies
Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes
Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development
Ascendis Pharma A/S
AstraZeneca PLC
Convergence Pharmaceuticals Ltd.
D-Pharm Ltd.
Delpor, Inc.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
Intra-Cellular Therapies, Inc.
KemPharm, Inc.
MarcoPolo Pharmaceuticals SA
Navigen Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc.
Omeros Corporation
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Reviva Pharmaceuticals Inc.
Richter Gedeon Nyrt.
SK Biopharmaceuticals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
Zogenix, Inc.
Zysis Limited
Bipolar Disorder (Manic Depression) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACP-005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aripiprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aripiprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aripiprazole CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BRDK-98958073 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cariprazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNV-1061436 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DP-VPA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Bipolar Disorder - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Cancer and Neurodegenerative Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Endoxifen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ITI-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KP-303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lurasidone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-2979165 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paliperidone palmitate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGW-5 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
quetiapine fumarate ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ramelteon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
risperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
risperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RP-5063 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SKL-PSY - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - Drug Profile
Product Description
Mechanism of Action
R&D Progress
uridine triacetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ziprasidone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bipolar Disorder (Manic Depression) - Recent Pipeline Updates
Bipolar Disorder (Manic Depression) - Dormant Projects
Bipolar Disorder (Manic Depression) - Dormant Projects
Bipolar Disorder (Manic Depression) - Discontinued Products
Bipolar Disorder (Manic Depression) - Product Development Milestones
Featured News & Press Releases
May 28, 2015: Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole
Mar 30, 2015: Sunovion Pharmaceuticals Europe to Present New Data on LATUDA (lurasidone) at the 23rd European Congress of Psychiatry
Jan 14, 2015: Sunovion Pharmaceuticals Files Patent Infringement Lawsuits Regarding Latuda
Jan 13, 2015: Germany's Federal Court Invalidates AstraZeneca’s Patent On Seroquel XR
Apr 03, 2014: Dainippon Sumitomo Pharma Announces Health Canada Approval of LATUDA (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Patients with Bipolar Depression
Mar 31, 2014: Forest Laboratories and Gedeon Richter Announce Positive Phase IIb Topline Results for Cariprazine for the Treatment of Bipolar Depression
Nov 13, 2013: Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly
Nov 01, 2013: Sunovion Announces Publication of Two Pivotal Studies Supporting FDA Approval of Latuda as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression in The American Journal of Psychiatry
Oct 29, 2013: A Phase I ready novel sodium channel blocker CNV1061436 for CNS disorders is added to the pipeline of clinical development candidates
Jun 28, 2013: Sunovion Pharmaceuticals Announces FDA Approval of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Bipolar Disorder (Manic Depression), H1 2015
Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Ascendis Pharma A/S, H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by AstraZeneca PLC, H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Convergence Pharmaceuticals Ltd., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by D-Pharm Ltd., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Delpor, Inc., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Eli Lilly and Company, H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Intas Pharmaceuticals Ltd., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Intra-Cellular Therapies, Inc., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by KemPharm, Inc., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by MarcoPolo Pharmaceuticals SA, H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Navigen Pharmaceuticals, Inc., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Neurocrine Biosciences, Inc., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Omeros Corporation, H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Pfizer Inc., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Reviva Pharmaceuticals Inc., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Richter Gedeon Nyrt., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Zogenix, Inc., H1 2015
Bipolar Disorder (Manic Depression) - Pipeline by Zysis Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Bipolar Disorder (Manic Depression) Therapeutics - Recent Pipeline Updates, H1 2015
Bipolar Disorder (Manic Depression) - Dormant Projects, H1 2015
Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..1), H1 2015
Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..2), H1 2015
Bipolar Disorder (Manic Depression) - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Bipolar Disorder (Manic Depression), H1 2015
Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report